Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis

Recruiting now · Phase 2

Conditions studied: Rheumatoid Arthritis (RA)

In brief

This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.

Key facts

Study ID

NCT07745426

Run by

Tanta University

People needed

66

Starts

2026-08-01

Expected to finish

2027-08-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) >2.6.
• Both sexes.
• Age ranges between 18 and 70 years old.
• Patients receiving conventional DMARDs

You may not qualify if…

• Pregnant and lactating females.
• Patients receiving biological DMARDs or targeted synthetic DMARDs.
• Patients with renal and hepatic dysfunction.
• Patients with other inflammatory/autoimmune diseases, active infection, or malignancies.
• Patients with bleeding disorders, receiving warfarin or other anticoagulants.
• Patients receiving antioxidants.
• Patients with hypersensitivity to study medications.

Where it is running

• Faculty of Pharmacy Tanta University — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.